252 lines
130 KiB
Text
252 lines
130 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK47312">
|
|
<meta name="ncbi_domain" content="gene">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK47312/?report=reader">
|
|
<meta name="ncbi_pagename" content="Legius Syndrome - GeneReviews® - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Legius Syndrome - GeneReviews® - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/gene/lhon/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/gene/lenz/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/gene/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="GeneReviews® [Internet]">
|
|
<meta name="citation_title" content="Legius Syndrome">
|
|
<meta name="citation_publisher" content="University of Washington, Seattle">
|
|
<meta name="citation_date" content="2020/08/06">
|
|
<meta name="citation_author" content="Eric Legius">
|
|
<meta name="citation_author" content="David Stevenson">
|
|
<meta name="citation_pmid" content="20945555">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK47312/">
|
|
<meta name="citation_keywords" content="Neurofibromatosis Type 1-Like Syndrome">
|
|
<meta name="citation_keywords" content="Neurofibromatosis Type 1-Like Syndrome">
|
|
<meta name="citation_keywords" content="Sprouty-related, EVH1 domain-containing protein 1">
|
|
<meta name="citation_keywords" content="SPRED1">
|
|
<meta name="citation_keywords" content="Legius Syndrome">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Legius Syndrome">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="University of Washington, Seattle">
|
|
<meta name="DC.Contributor" content="Eric Legius">
|
|
<meta name="DC.Contributor" content="David Stevenson">
|
|
<meta name="DC.Date" content="2020/08/06">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK47312/">
|
|
<meta name="description" content="Legius syndrome is characterized by multiple café au lait macules without neurofibromas or other tumor manifestations of neurofibromatosis type 1 (NF1). Additional clinical manifestations reported commonly include intertriginous freckling, lipomas, macrocephaly, and learning disabilities / attention-deficit/hyperactivity disorder (ADHD) / developmental delays. Current knowledge of the natural history of Legius syndrome is based on the clinical manifestations of fewer than 300 individuals with a molecularly confirmed diagnosis; better delineation of the clinical manifestations and natural history of Legius syndrome will likely occur as more affected individuals are identified.">
|
|
<meta name="og:title" content="Legius Syndrome">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Legius syndrome is characterized by multiple café au lait macules without neurofibromas or other tumor manifestations of neurofibromatosis type 1 (NF1). Additional clinical manifestations reported commonly include intertriginous freckling, lipomas, macrocephaly, and learning disabilities / attention-deficit/hyperactivity disorder (ADHD) / developmental delays. Current knowledge of the natural history of Legius syndrome is based on the clinical manifestations of fewer than 300 individuals with a molecularly confirmed diagnosis; better delineation of the clinical manifestations and natural history of Legius syndrome will likely occur as more affected individuals are identified.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK47312/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/gene/legius/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK47312/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8E74497C87DFC100000000003A0036.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK47312/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/gene/lhon/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Legius Syndrome</div><div class="j">GeneReviews® [Internet]</div></div><div class="tail"><a href="/books/n/gene/lenz/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK47312/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK47312/&text=Legius%20Syndrome"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/gene/?report=reader">Title Information</a><a href="/books/n/gene/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK47312/?report=classic">Switch to classic view</a><a href="/books/NBK47312/pdf/Bookshelf_NBK47312.pdf">PDF (492K)</a><a href="/books/NBK47312/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK47312%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8E74497C87DFC100000000003A0036.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK47312_"><span class="title" itemprop="name">Legius Syndrome</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: Neurofibromatosis Type 1-Like Syndrome</div><p class="contribs">Legius E, Stevenson D.</p><p class="fm-aai"><a href="#_NBK47312_pubdet_">Publication Details</a></p><p><em>Estimated reading time: 21 minutes</em></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="legius.Summary" itemprop="description"><h2 id="_legius_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Legius syndrome is characterized by multiple café au lait macules without neurofibromas or other tumor manifestations of neurofibromatosis type 1 (NF1). Additional clinical manifestations reported commonly include intertriginous freckling, lipomas, macrocephaly, and learning disabilities / attention-deficit/hyperactivity disorder (ADHD) / developmental delays. Current knowledge of the natural history of Legius syndrome is based on the clinical manifestations of fewer than 300 individuals with a molecularly confirmed diagnosis; better delineation of the clinical manifestations and natural history of Legius syndrome will likely occur as more affected individuals are identified.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of Legius syndrome is established in a proband with suggestive findings and a heterozygous pathogenic variant in <i>SPRED1</i> identified by molecular genetic testing.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Consideration of behavioral modification and/or pharmacologic therapy for those with ADHD; physical, speech, and occupational therapy for those with identified developmental delays; and individualized education plans for those with learning disorders.</p><p><i>Surveillance:</i> Routine screening for developmental delays and behavioral and learning problems.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Legius syndrome is inherited in an autosomal dominant manner. Many affected individuals have an affected parent. Each child of an individual with Legius syndrome has a 50% chance of inheriting the pathogenic variant and developing clinical features of the disorder. Preimplantation genetic testing or prenatal testing for pregnancies at increased risk is possible if the <i>SPRED1</i> pathogenic variant has been identified in an affected family member.</p></div></div><div id="legius.Diagnosis"><h2 id="_legius_Diagnosis_">Diagnosis</h2><div id="legius.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Legius syndrome <b>should be suspected</b> in an individual who:</p><ul><li class="half_rhythm"><div>Has pigmentary dysplasia consisting of café au lait macules, with or without intertriginous freckling; and</div></li><li class="half_rhythm"><div>Lacks the nonpigmentary clinical diagnostic manifestations of <a href="/books/n/gene/nf1/?report=reader">neurofibromatosis type 1</a> (NF1) (e.g., Lisch nodules, neurofibromas, optic pathway glioma, sphenoid wing dysplasia, long bone dysplasia).</div></li></ul></div><div id="legius.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnostic criteria for Legius syndrome are met if at least two of the following criteria are present:</p><ul><li class="half_rhythm"><div>Five or more café au lait macules bilaterally distributed and no other NF1-related diagnostic criteria except for axillary or inguinal freckling</div></li><li class="half_rhythm"><div>A heterozygous pathogenic (or likely pathogenic) variant in <i>SPRED1</i> in 100% of cells from unaffected tissue (see <a href="/books/NBK47312/table/legius.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-ob="figoblegiusTmoleculargenetictestingused">Table 1</a>)</div></li><li class="half_rhythm"><div>A parent with the diagnosis of Legius syndrome by the above criteria</div></li></ul><p>Note: (1) Per ACMG variant interpretation guidelines, the terms "pathogenic variants" and "likely pathogenic variants" are synonymous in a clinical setting, meaning that both are considered diagnostic and both can be used for clinical decision making. Reference to "pathogenic variants" in this section is understood to include any likely pathogenic variants. (2) Identification of a heterozygous <i>SPRED1</i> variant of uncertain significance does not establish or rule out the diagnosis of this disorder.</p><p><b>Molecular testing approaches</b> can include:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-gene testing.</b> Sequence analysis of <i>SPRED1</i> to detect small intragenic deletions/insertions and missense, nonsense, and splice site variants. Note: Depending on the sequencing method used, single-exon, multiexon, or whole-gene deletions/duplications may not be detected. If no variant is detected by the sequencing method used, the next step is to perform gene-targeted deletion/duplication analysis to detect exon and whole-gene deletions or duplications.</div></li><li class="half_rhythm"><div class="half_rhythm">A <b>multigene pane</b>l that includes <i>SPRED1</i> and other genes of interest (see <a href="#legius.Differential_Diagnosis">Differential Diagnosis</a>). Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/?report=reader#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/?report=reader#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><p>Note: Opinions differ on the appropriate approach when clinical information and family history cannot distinguish between NF1 and Legius syndrome. This is the case in individuals with only café au lait macules with or without freckling but no other signs of NF1. The assessment of pros and cons of molecular testing requires consideration of the circumstances unique to each individual, including (but not limited to) the following:</p><ul><li class="half_rhythm"><div>Clinical findings and family history</div></li><li class="half_rhythm"><div>Age of the individual</div></li><li class="half_rhythm"><div>Differences in recommended clinical management when the diagnosis of NF1 or Legius syndrome is established with certainty vs when the diagnosis of neither can be established with confidence</div></li><li class="half_rhythm"><div>Psychological burden of a diagnosis or lack thereof</div></li><li class="half_rhythm"><div>Costs of testing and surveillance</div></li><li class="half_rhythm"><div>Odds of identifying a diagnosis of NF1 vs Legius syndrome in those with phenotype limited to pigmentary findings</div></li></ul><p>For various approaches, see <a class="bibr" href="#legius.REF.messiaen.2009.2111" rid="legius.REF.messiaen.2009.2111">Messiaen et al [2009]</a>, <a class="bibr" href="#legius.REF.pasmant.2009.1131" rid="legius.REF.pasmant.2009.1131">Pasmant et al [2009]</a>, <a class="bibr" href="#legius.REF.stevenson.2009.2150" rid="legius.REF.stevenson.2009.2150">Stevenson & Viskochil [2009]</a>, <a class="bibr" href="#legius.REF.muramzborovski.2010.1203" rid="legius.REF.muramzborovski.2010.1203">Muram-Zborovski et al [2010]</a>, <a class="bibr" href="#legius.REF.denayer.2011a.e1985" rid="legius.REF.denayer.2011a.e1985">Denayer et al [2011a]</a>, <a class="bibr" href="#legius.REF.brems.2012.1538" rid="legius.REF.brems.2012.1538">Brems et al [2012]</a>, <a class="bibr" href="#legius.REF.evans.2016.212" rid="legius.REF.evans.2016.212">Evans et al [2016]</a>, and <a class="bibr" href="#legius.REF.castellanos.2020.264" rid="legius.REF.castellanos.2020.264">Castellanos et al [2020]</a>.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figlegiusTmoleculargenetictestingused"><a href="/books/NBK47312/table/legius.T.molecular_genetic_testing_used/?report=objectonly" target="object" title="Table 1. " class="img_link icnblk_img" rid-ob="figoblegiusTmoleculargenetictestingused"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="legius.T.molecular_genetic_testing_used"><a href="/books/NBK47312/table/legius.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-ob="figoblegiusTmoleculargenetictestingused">Table 1. </a></h4><p class="float-caption no_bottom_margin">Molecular Genetic Testing Used in Legius Syndrome </p></div></div></div></div><div id="legius.Clinical_Characteristics"><h2 id="_legius_Clinical_Characteristics_">Clinical Characteristics</h2><div id="legius.Clinical_Description"><h3>Clinical Description</h3><p>Of note, the phenotype of Legius syndrome is based on the reports of relatively few (<300) individuals, in which the primary focus was on individuals with the overlapping pigmentary manifestations of <a href="/books/n/gene/nf1/?report=reader">neurofibromatosis type 1</a> (NF1).</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figlegiusTlegiussyndromefrequencyofse"><a href="/books/NBK47312/table/legius.T.legius_syndrome_frequency_of_se/?report=objectonly" target="object" title="Table 2. " class="img_link icnblk_img" rid-ob="figoblegiusTlegiussyndromefrequencyofse"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="legius.T.legius_syndrome_frequency_of_se"><a href="/books/NBK47312/table/legius.T.legius_syndrome_frequency_of_se/?report=objectonly" target="object" rid-ob="figoblegiusTlegiussyndromefrequencyofse">Table 2. </a></h4><p class="float-caption no_bottom_margin">Legius Syndrome: Frequency of Select Features </p></div></div><p><b>Skin findings.</b> Almost invariably, individuals with Legius syndrome present with café au lait macules. In some instances, freckling of the axillary/groin region is present. Two individuals (a male age 60 years and a child age 2 years), each with a presumed pathogenic <i>SPRED1</i> variant, have been reported with no café au lait macules or freckling [<a class="bibr" href="#legius.REF.brems.2007.1120" rid="legius.REF.brems.2007.1120">Brems et al 2007</a>, <a class="bibr" href="#legius.REF.messiaen.2009.2111" rid="legius.REF.messiaen.2009.2111">Messiaen et al 2009</a>]. The lack of pigmentary manifestations in the child was possibly a result of the child's young age. It is known that café au lait macules can fade away in older individuals with NF1. The number of café au lait macules increases with age in infants, similar to what is observed in NF1 [Author, personal observation].</p><p><b>Macrocephaly.</b> Absolute or relative macrocephaly has been seen in children and adults with Legius syndrome. However, the frequency of macrocephaly varied in different reports: head circumference was at or above the 97th centile in approximately 40% of individuals in one cohort [<a class="bibr" href="#legius.REF.brems.2007.1120" rid="legius.REF.brems.2007.1120">Brems et al 2007</a>] but above the 95th centile in only one of 18 individuals in another cohort [<a class="bibr" href="#legius.REF.pasmant.2009.1131" rid="legius.REF.pasmant.2009.1131">Pasmant et al 2009</a>].</p><p><b>Stature.</b> Absolute short stature has not been frequently noted in most series (although <a class="bibr" href="#legius.REF.denayer.2011a.e1985" rid="legius.REF.denayer.2011a.e1985">Denayer et al [2011a]</a> reported it in 31%). <a class="bibr" href="#legius.REF.brems.2007.1120" rid="legius.REF.brems.2007.1120">Brems et al [2007]</a> reported that in 52% of individuals, height was greater than the 50th centile. Growth charts for Legius syndrome have not been published.</p><p><b>Neurobehavioral and developmental problems</b> are observed in individuals with Legius syndrome, but in many instances detailed descriptions are lacking. <a class="bibr" href="#legius.REF.messiaen.2009.2111" rid="legius.REF.messiaen.2009.2111">Messiaen et al [2009]</a> reported three individuals who had hyperactivity and two who had attention deficits. Of the six individuals with developmental abnormalities described by <a class="bibr" href="#legius.REF.messiaen.2009.2111" rid="legius.REF.messiaen.2009.2111">Messiaen et al [2009]</a>, all had speech and/or language delays as the primary or only delay. In the 12 individuals with Legius syndrome described by <a class="bibr" href="#legius.REF.spurlock.2009.431" rid="legius.REF.spurlock.2009.431">Spurlock et al [2009]</a>, no learning or developmental problems were noted in the probands. <a class="bibr" href="#legius.REF.denayer.2011a.e1985" rid="legius.REF.denayer.2011a.e1985">Denayer et al [2011a]</a> described five children with motor delay and five with speech delay, three individuals with ADHD, and 14 of 25 individuals with learning difficulties. Learning disabilities were further reported by <a class="bibr" href="#legius.REF.benelli.2015.8" rid="legius.REF.benelli.2015.8">Benelli et al [2015]</a>, <a class="bibr" href="#legius.REF.sakai.2015.703" rid="legius.REF.sakai.2015.703">Sakai et al [2015]</a>, <a class="bibr" href="#legius.REF.sekelska.2017.205" rid="legius.REF.sekelska.2017.205">Sekelska et al [2017]</a>, and <a class="bibr" href="#legius.REF.witkowski.2020.e1180" rid="legius.REF.witkowski.2020.e1180">Witkowski et al [2020]</a> in five individuals.</p><p>The cognitive issues in individuals with Legius syndrome are likely milder than those observed in NF1. A study of 15 individuals with Legius syndrome by <a class="bibr" href="#legius.REF.denayer.2011b.123" rid="legius.REF.denayer.2011b.123">Denayer et al [2011b]</a> showed a lower performance IQ in children with Legius syndrome compared to their unaffected family members, although the full-scale IQ did not differ. <a class="bibr" href="#legius.REF.laycockvan_spyk.2011.93" rid="legius.REF.laycockvan_spyk.2011.93">Laycock-van Spyk et al [2011]</a> reported one individual with cognitive impairment with an IQ of 68.</p><p><b>Brain imaging.</b> Two individuals had T<sub>2</sub>-weighted hyperintense lesions on brain imaging; thus, the presence of such lesions cannot be used to differentiate between Legius syndrome and NF1 [<a class="bibr" href="#legius.REF.denayer.2011a.e1985" rid="legius.REF.denayer.2011a.e1985">Denayer et al 2011a</a>].</p><p><b>Vascular anomalies.</b> A small number of vascular anomalies have been reported, but the descriptions are incomplete and different in each instance. The vascular abnormalities were listed as "tuberous hemangioma," "inguinal hemangioma," "large right temporal venous anomaly in brain," and "vascular anomaly left lower leg." Additional data are needed to determine if these reported vascular anomalies are tumors or malformations, and whether there is an increase of vascular anomalies in individuals with Legius syndrome.</p><p><b>Rare features</b> reported in more than one individual:</p><ul><li class="half_rhythm"><div>Hearing loss in four individuals [<a class="bibr" href="#legius.REF.messiaen.2009.2111" rid="legius.REF.messiaen.2009.2111">Messiaen et al 2009</a>, <a class="bibr" href="#legius.REF.denayer.2011a.e1985" rid="legius.REF.denayer.2011a.e1985">Denayer et al 2011a</a>]</div></li><li class="half_rhythm"><div>Seizures in six individuals [<a class="bibr" href="#legius.REF.messiaen.2009.2111" rid="legius.REF.messiaen.2009.2111">Messiaen et al 2009</a>, <a class="bibr" href="#legius.REF.denayer.2011a.e1985" rid="legius.REF.denayer.2011a.e1985">Denayer et al 2011a</a>, <a class="bibr" href="#legius.REF.laycockvan_spyk.2011.93" rid="legius.REF.laycockvan_spyk.2011.93">Laycock-van Spyk et al 2011</a>, <a class="bibr" href="#legius.REF.benelli.2015.8" rid="legius.REF.benelli.2015.8">Benelli et al 2015</a>, <a class="bibr" href="#legius.REF.sakai.2015.703" rid="legius.REF.sakai.2015.703">Sakai et al 2015</a>]</div></li><li class="half_rhythm"><div>Polydactyly in three individuals [<a class="bibr" href="#legius.REF.messiaen.2009.2111" rid="legius.REF.messiaen.2009.2111">Messiaen et al 2009</a>, <a class="bibr" href="#legius.REF.denayer.2011a.e1985" rid="legius.REF.denayer.2011a.e1985">Denayer et al 2011a</a>]</div></li><li class="half_rhythm"><div>Scoliosis in five individuals [<a class="bibr" href="#legius.REF.denayer.2011a.e1985" rid="legius.REF.denayer.2011a.e1985">Denayer et al 2011a</a>, <a class="bibr" href="#legius.REF.laycockvan_spyk.2011.93" rid="legius.REF.laycockvan_spyk.2011.93">Laycock-van Spyk et al 2011</a>]</div></li><li class="half_rhythm"><div>Pulmonic valve stenosis in three individuals [<a class="bibr" href="#legius.REF.brems.2007.1120" rid="legius.REF.brems.2007.1120">Brems et al 2007</a>, <a class="bibr" href="#legius.REF.messiaen.2009.2111" rid="legius.REF.messiaen.2009.2111">Messiaen et al 2009</a>, <a class="bibr" href="#legius.REF.witkowski.2020.e1180" rid="legius.REF.witkowski.2020.e1180">Witkowski et al 2020</a>]</div></li></ul><p><b>Other.</b> Examples of other findings reported in isolated or only a few individuals include fifth finger clinodactyly, Chiari I malformation, hypotonia, cataract, nephrolithiasis, urethral meatal stenosis, mitral valve prolapse, paroxysmal atrial tachycardia, tubular colonic adenoma, progressive dystonia, xanthelasmas, desmoid tumor, vestibular schwannoma, tenosynovial giant cell tumor, dermoid tumor of the ovary, non-small-cell lung cancer, Wilms tumor, and monoblastic acute leukemia. Observations of clinical findings in a single individual should be taken with caution because chance occurrence cannot be distinguished from specific disease associations.</p><p><b>Tumor risk.</b> Legius syndrome in general lacks the tumor manifestations typically observed in NF1 (i.e., Lisch nodules, neurofibromas, and central nervous system tumors). One group has suggested that individuals with Legius syndrome are at an increased risk for leukemia [<a class="bibr" href="#legius.REF.pasmant.2009.1131" rid="legius.REF.pasmant.2009.1131">Pasmant et al 2009</a>, <a class="bibr" href="#legius.REF.pasmant.2015a.631" rid="legius.REF.pasmant.2015a.631">Pasmant et al 2015a</a>]. There has been a report of acute myeloblastic leukemia in one individual by <a class="bibr" href="#legius.REF.pasmant.2009.1131" rid="legius.REF.pasmant.2009.1131">Pasmant et al [2009]</a>, and this group subsequently screened 230 pediatric lymphoblastic and acute myeloblastic leukemias and found a loss-of-function frameshift <i>SPRED1</i> variant in an individual with Legius syndrome [<a class="bibr" href="#legius.REF.pasmant.2015a.631" rid="legius.REF.pasmant.2015a.631">Pasmant et al 2015a</a>]. Further studies are needed to assess the potential risk for cancers in Legius syndrome, particularly given that <i>SPRED1</i> is part of the RAS-MAPK signal transduction pathway, a pathway involved in several neoplasms.</p></div><div id="legius.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>No genotype-phenotype correlations have been identified.</p></div><div id="legius.Penetrance"><h3>Penetrance</h3><p>The vast majority of individuals with <i>SPRED1</i> pathogenic variants have café au lait macules and/or freckling; however, the age of pigment penetrance is not established. Only two individuals (a male age 60 years and a child age 2 years), each with a presumed <i>SPRED1</i> pathogenic variant, were reported not to have café au lait macules or freckling [<a class="bibr" href="#legius.REF.brems.2007.1120" rid="legius.REF.brems.2007.1120">Brems et al 2007</a>, <a class="bibr" href="#legius.REF.messiaen.2009.2111" rid="legius.REF.messiaen.2009.2111">Messiaen et al 2009</a>].</p><p>Some very young children may not have developed café au lait macules yet, and in older individuals the café au lait macules may have faded away. Some adolescents or young adults show only two or three café au lait macules, and the syndrome may be underdiagnosed.</p></div><div id="legius.Nomenclature"><h3>Nomenclature</h3><p>The majority of individuals with <i>SPRED1</i> pathogenic variants share the pigmentary manifestations but lack the tumor findings associated with NF1. It is not a form of neurofibromatosis because no neurofibromas have been reported. To clearly delineate this point in counseling sessions and to avoid confusion between NF1 and NF1-like syndrome, the name "Legius syndrome" was chosen and fulfills its purpose.</p></div><div id="legius.Prevalence"><h3>Prevalence</h3><p>The prevalence of Legius syndrome is estimated at 1:46,000-1:75,000 based on the fraction of children with a <i>SPRED1</i> pathogenic variant in cohorts of children followed at NF clinics [<a class="bibr" href="#legius.REF.messiaen.2009.2111" rid="legius.REF.messiaen.2009.2111">Messiaen et al 2009</a>, <a class="bibr" href="#legius.REF.pasmant.2015b.596" rid="legius.REF.pasmant.2015b.596">Pasmant et al 2015b</a>, <a class="bibr" href="#legius.REF.evans.2016.212" rid="legius.REF.evans.2016.212">Evans et al 2016</a>, <a class="bibr" href="#legius.REF.giugliano.2019.580" rid="legius.REF.giugliano.2019.580">Giugliano et al 2019</a>].</p></div></div><div id="legius.Genetically_Related_Allelic_Disor"><h2 id="_legius_Genetically_Related_Allelic_Disor_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with germline pathogenic variants in <i>SPRED1.</i></p><p><b>Sporadic tumors</b> (including mucosal and acral melanomas) occurring as single tumors in the absence of any other findings of Legius syndrome frequently harbor somatic variants in <i>SPRED1</i> that are <b>not</b> present in the germline [<a class="bibr" href="#legius.REF.ablain.2018.1055" rid="legius.REF.ablain.2018.1055">Ablain et al 2018</a>, <a class="bibr" href="#legius.REF.newell.2019.3163" rid="legius.REF.newell.2019.3163">Newell et al 2019</a>, <a class="bibr" href="#legius.REF.yeh.2019.1068" rid="legius.REF.yeh.2019.1068">Yeh et al 2019</a>]. In these circumstances predisposition to these tumors is not heritable.</p></div><div id="legius.Differential_Diagnosis"><h2 id="_legius_Differential_Diagnosis_">Differential Diagnosis</h2><p>Of primary importance in the clinical delineation of Legius syndrome is establishing the absence of other manifestations associated with the large number of other syndromes with multiple café au lait macules (most notably <a href="/books/n/gene/nf1/?report=reader">neurofibromatosis type 1</a>; see also <a href="/books/NBK47312/table/legius.T.disorders_with_multiple_caf_au/?report=objectonly" target="object" rid-ob="figoblegiusTdisorderswithmultiplecafau">Table 3</a>). Although the diagnosis of Legius syndrome is difficult to make clinically with certainty without identification of a <i>SPRED1</i> pathogenic variant, the lack of additional clinical features, especially in older individuals, can help to differentiate Legius syndrome from other conditions. The surveillance in neurofibromatosis type 1 is very different from the surveillance in Legius syndrome, stressing the importance of a correct diagnosis.</p><p><b>Neurofibromatosis type 1 (NF1)</b> is most frequently confused with Legius syndrome, as some individuals with Legius syndrome fulfill the clinical diagnostic criteria for NF1 [<a class="bibr" href="#legius.REF.nih.1988.172" rid="legius.REF.nih.1988.172">NIH 1988</a>, <a class="bibr" href="#legius.REF.gutmann.1997.51" rid="legius.REF.gutmann.1997.51">Gutmann et al 1997</a>]. About 8% of children with six or more café au lait spots and no other clinical features of NF1 have Legius syndrome [<a class="bibr" href="#legius.REF.evans.2016.212" rid="legius.REF.evans.2016.212">Evans et al 2016</a>]. Distinguishing Legius syndrome from NF1 is sometimes impossible on the basis of clinical features alone in a young child because the multiple cutaneous neurofibromas and Lisch nodules characteristic of NF1 do not usually arise until later in childhood or adolescence. Examination of the parents for signs of Legius syndrome or NF1 may distinguish the two conditions, but in simplex cases reevaluation of the proband after adolescence or molecular testing may be necessary to establish the diagnosis. The phenotypes associated with specific <i>NF1</i> pathogenic variants are similar to Legius syndrome in some instances. A described genotype-phenotype correlation with the <i>NF1</i> 3-bp deletion resulting in removal of a methionine residue (c.2970_2972delAAT) [<a class="bibr" href="#legius.REF.koczkowska.2019.867" rid="legius.REF.koczkowska.2019.867">Koczkowska et al 2019</a>] and missense variants of p.Arg1809 [<a class="bibr" href="#legius.REF.rojnueangnit.2015.1052" rid="legius.REF.rojnueangnit.2015.1052">Rojnueangnit et al 2015</a>] result in an attenuated NF1 phenotype with relative lack of neurofibromas.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figlegiusTdisorderswithmultiplecafau"><a href="/books/NBK47312/table/legius.T.disorders_with_multiple_caf_au/?report=objectonly" target="object" title="Table 3. " class="img_link icnblk_img" rid-ob="figoblegiusTdisorderswithmultiplecafau"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="legius.T.disorders_with_multiple_caf_au"><a href="/books/NBK47312/table/legius.T.disorders_with_multiple_caf_au/?report=objectonly" target="object" rid-ob="figoblegiusTdisorderswithmultiplecafau">Table 3. </a></h4><p class="float-caption no_bottom_margin">Disorders with Multiple Café au Lait Macules of Interest in the Differential Diagnosis of Legius Syndrome </p></div></div><p>
|
|
<b>Other disorders with multiple café au lait macules</b>
|
|
</p><ul><li class="half_rhythm"><div><a href="/books/n/gene/rss/?report=reader"><b>Silver-Russell syndrome</b></a><b>.</b> Additional clinical features include marked prenatal and postnatal growth restriction and body asymmetry.</div></li><li class="half_rhythm"><div><b>Autosomal dominant café au lait spots</b> (OMIM <a href="https://omim.org/entry/114030" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">114030</a>). Several families with multiple café au lait macules inherited in an autosomal dominant pattern have been described. It is possible that some of these families harbor a <i>SPRED1</i> pathogenic variant, although this phenotype in at least one family did not segregate with markers within the <i>SPRED1</i> locus [<a class="bibr" href="#legius.REF.nystr_m.2009.693" rid="legius.REF.nystr_m.2009.693">Nyström et al 2009</a>].</div></li></ul></div><div id="legius.Management"><h2 id="_legius_Management_">Management</h2><div id="legius.Evaluations_Following_Initial_Dia"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of an individual with Legius syndrome, the evaluations summarized in <a href="/books/NBK47312/table/legius.T.recommended_evaluations_followi/?report=objectonly" target="object" rid-ob="figoblegiusTrecommendedevaluationsfollowi">Table 4</a> (if not performed as part of the evaluation that led to the diagnosis) are recommended.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figlegiusTrecommendedevaluationsfollowi"><a href="/books/NBK47312/table/legius.T.recommended_evaluations_followi/?report=objectonly" target="object" title="Table 4. " class="img_link icnblk_img" rid-ob="figoblegiusTrecommendedevaluationsfollowi"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="legius.T.recommended_evaluations_followi"><a href="/books/NBK47312/table/legius.T.recommended_evaluations_followi/?report=objectonly" target="object" rid-ob="figoblegiusTrecommendedevaluationsfollowi">Table 4. </a></h4><p class="float-caption no_bottom_margin">Recommended Evaluations Following Initial Diagnosis in Individuals with Legius Syndrome </p></div></div></div><div id="legius.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figlegiusTtreatmentofmanifestationsin"><a href="/books/NBK47312/table/legius.T.treatment_of_manifestations_in/?report=objectonly" target="object" title="Table 5. " class="img_link icnblk_img" rid-ob="figoblegiusTtreatmentofmanifestationsin"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="legius.T.treatment_of_manifestations_in"><a href="/books/NBK47312/table/legius.T.treatment_of_manifestations_in/?report=objectonly" target="object" rid-ob="figoblegiusTtreatmentofmanifestationsin">Table 5. </a></h4><p class="float-caption no_bottom_margin">Treatment of Manifestations in Individuals with Legius Syndrome </p></div></div></div><div id="legius.Surveillance"><h3>Surveillance</h3><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figlegiusTrecommendedsurveillanceforin"><a href="/books/NBK47312/table/legius.T.recommended_surveillance_for_in/?report=objectonly" target="object" title="Table 6. " class="img_link icnblk_img" rid-ob="figoblegiusTrecommendedsurveillanceforin"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="legius.T.recommended_surveillance_for_in"><a href="/books/NBK47312/table/legius.T.recommended_surveillance_for_in/?report=objectonly" target="object" rid-ob="figoblegiusTrecommendedsurveillanceforin">Table 6. </a></h4><p class="float-caption no_bottom_margin">Recommended Surveillance for Individuals with Legius Syndrome </p></div></div></div><div id="legius.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#legius.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for genetic counseling purposes.</p></div><div id="legius.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="https://clinicaltrials.gov/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">ClinicalTrials.gov</a> in the US and <a href="https://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="legius.Genetic_Counseling"><h2 id="_legius_Genetic_Counseling_">Genetic Counseling</h2><p>
|
|
<i>Genetic counseling is the process of providing individuals and families with
|
|
information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them
|
|
make informed medical and personal decisions. The following section deals with genetic
|
|
risk assessment and the use of family history and genetic testing to clarify genetic
|
|
status for family members; it is not meant to address all personal, cultural, or
|
|
ethical issues that may arise or to substitute for consultation with a genetics
|
|
professional</i>. —ED.</p><div id="legius.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Legius syndrome is inherited in an autosomal dominant manner.</p></div><div id="legius.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p>
|
|
<b>Parents of a proband</b>
|
|
</p><ul><li class="half_rhythm"><div class="half_rhythm">Many individuals diagnosed with Legius syndrome have an affected parent.</div></li><li class="half_rhythm"><div class="half_rhythm">Some individuals diagnosed with Legius syndrome have the disorder as the result of a <i>de novo</i> pathogenic variant; the proportion of individuals with Legius syndrome caused by a <i>de novo</i> pathogenic variant is unknown. One report stated that six of 23 probands with <i>SPRED1</i> pathogenic variants in a clinical cohort had <i>de novo</i> variants [<a class="bibr" href="#legius.REF.messiaen.2009.2111" rid="legius.REF.messiaen.2009.2111">Messiaen et al 2009</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Molecular genetic testing is recommended for the parents of a proband with an apparent <i>de novo</i> pathogenic variant (i.e., a proband who appears to be the only affected family member).</div></li><li class="half_rhythm"><div class="half_rhythm">If the pathogenic variant found in the proband cannot be detected in the leukocyte DNA of either parent, possible explanations include a <i>de novo</i> pathogenic variant in the proband or germline mosaicism in a parent.* Though theoretically possible, no instances of a proband inheriting a pathogenic variant from a parent with germline mosaicism have been reported.</div><div class="half_rhythm">* Misattributed parentage can also be explored as an alternative explanation for an apparent <i>de novo</i> pathogenic variant.</div></li><li class="half_rhythm"><div class="half_rhythm">The family history of some individuals diagnosed with Legius syndrome may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent. Therefore, an apparently negative family history cannot be confirmed unless molecular genetic testing has demonstrated that neither parent is heterozygous for the <i>SPRED1</i> pathogenic variant identified in the proband.</div><div class="half_rhythm">Note: If the parent is the individual in whom the pathogenic variant first occurred, the parent may have somatic/germline mosaicism for the pathogenic variant and may be mildly/minimally affected. (Segmental distribution of café au lait macules as a result of somatic mosaicism for a <i>SPRED1</i> pathogenic variant has been observed in two individuals but is very rare [<a class="bibr" href="#legius.REF.jobling.2017.1077" rid="legius.REF.jobling.2017.1077">Jobling et al 2017</a>; Author, unpublished data].)</div></li></ul><p><b>Sibs of a proband.</b> The risk to the sibs of the proband depends on the genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div>If a parent of the proband is affected and/or is known to have the pathogenic variant identified in the proband, the risk to the sibs of inheriting the pathogenic variant is 50%.</div></li><li class="half_rhythm"><div>All sibs who inherit a pathogenic <i>SPRED1</i> variant will develop some clinical features of Legius syndrome, but there is a high variability in the number and age of onset of café au lait macules (see <a href="#legius.Penetrance">Penetrance</a>).</div></li><li class="half_rhythm"><div>If the proband has a known <i>SPRED1</i> pathogenic variant that cannot be detected in the leukocyte DNA of either parent, the recurrence risk to sibs is estimated to be 1% because of the possibility of parental germline mosaicism [<a class="bibr" href="#legius.REF.rahbari.2016.126" rid="legius.REF.rahbari.2016.126">Rahbari et al 2016</a>].</div></li><li class="half_rhythm"><div>If the parents have not been tested for the <i>SPRED1</i> pathogenic variant but are clinically unaffected, the risk to the sibs of a proband appears to be low. However, sibs of a proband with clinically unaffected parents are still presumed to be at increased risk for Legius syndrome because of the possibility of reduced penetrance in a heterozygous parent or the theoretic possibility of parental germline mosaicism.</div></li></ul><p><b>Offspring of a proband.</b> Each child of an individual with Legius syndrome has a 50% chance of inheriting the <i>SPRED1</i> pathogenic variant.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the proband's parents: if a parent has the <i>SPRED1</i> pathogenic variant, the parent's family members may be at risk.</p></div><div id="legius.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>
|
|
<b>Family planning</b>
|
|
</p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</div></li></ul><p><b>DNA banking.</b> Because it is likely that testing methodology and our understanding of genes, pathogenic mechanisms, and diseases will improve in the future, consideration should be given to banking DNA from probands in whom a molecular diagnosis has not been confirmed (i.e., the causative pathogenic mechanism is unknown).</p></div><div id="legius.Prenatal_Testing_and_Preimplantat"><h3>Prenatal Testing and Preimplantation Genetic Testing</h3><p>Once the <i>SPRED1</i> pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing for Legius syndrome are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing. While most centers would consider use of prenatal testing to be a personal decision, discussion of these issues may be helpful.</p></div></div><div id="legius.Resources"><h2 id="_legius_Resources_">Resources</h2><p>
|
|
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
|
|
support organizations and/or registries for the benefit of individuals with this disorder
|
|
and their families. GeneReviews is not responsible for the information provided by other
|
|
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/?report=reader">here</a>.</i></p>
|
|
<ul><li class="half_rhythm"><div>
|
|
<b>RASopathies Network</b>
|
|
</div><div><b>Email:</b> info@rasopathiesnet.org</div><div>
|
|
<a href="http://rasopathiesnet.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">www.rasopathiesnet.org</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<b>Children's Tumor Foundation</b>
|
|
</div><div><b>Phone:</b> 800-323-7938</div><div><b>Email:</b> info@ctf.org</div><div>
|
|
<a href="http://www.ctf.org" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">www.ctf.org</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<b>Nerve Tumours UK</b>
|
|
</div><div>United Kingdom</div><div>
|
|
<a href="https://nervetumours.org.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">www.nervetumours.org.uk</a>
|
|
</div></li></ul>
|
|
</div><div id="legius.Molecular_Genetics"><h2 id="_legius_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —</i>ED.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figlegiusmolgenTA"><a href="/books/NBK47312/table/legius.molgen.TA/?report=objectonly" target="object" title="Table A." class="img_link icnblk_img" rid-ob="figoblegiusmolgenTA"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="legius.molgen.TA"><a href="/books/NBK47312/table/legius.molgen.TA/?report=objectonly" target="object" rid-ob="figoblegiusmolgenTA">Table A.</a></h4><p class="float-caption no_bottom_margin">Legius Syndrome: Genes and Databases </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figlegiusmolgenTB"><a href="/books/NBK47312/table/legius.molgen.TB/?report=objectonly" target="object" title="Table B." class="img_link icnblk_img" rid-ob="figoblegiusmolgenTB"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="legius.molgen.TB"><a href="/books/NBK47312/table/legius.molgen.TB/?report=objectonly" target="object" rid-ob="figoblegiusmolgenTB">Table B.</a></h4><p class="float-caption no_bottom_margin">OMIM Entries for Legius Syndrome (View All in OMIM) </p></div></div><div id="legius.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p><i>SPRED1</i> encodes Spred1, a protein that negatively regulates Ras-MAPK signaling. Spred1 functional domains include:</p><ul><li class="half_rhythm"><div>N-terminal EVH-1 domain</div></li><li class="half_rhythm"><div>Central KIT binding domain</div></li><li class="half_rhythm"><div>C-terminal SPRY domain</div></li></ul><p>Spred1 belongs to a family of proteins that are negative regulators of the Ras/ERK pathway. Spred1 negatively regulates the Ras/ERK pathway by inhibiting Raf1 kinase activation [<a class="bibr" href="#legius.REF.wakioka.2001.647" rid="legius.REF.wakioka.2001.647">Wakioka et al 2001</a>, <a class="bibr" href="#legius.REF.tidyman.2009.230" rid="legius.REF.tidyman.2009.230">Tidyman & Rauen 2009</a>]. Spred1 has also been shown to interact with neurofibromin to bring it to plasma membrane-bound Ras peptides [<a class="bibr" href="#legius.REF.stowe.2012.1421" rid="legius.REF.stowe.2012.1421">Stowe et al 2012</a>]. Specific interacting domains in SPRED1 and neurofibromin have been identified [<a class="bibr" href="#legius.REF.dunzendorfermatt.2016.7497" rid="legius.REF.dunzendorfermatt.2016.7497">Dunzendorfer-Matt et al 2016</a>, <a class="bibr" href="#legius.REF.hirata.2016.3124" rid="legius.REF.hirata.2016.3124">Hirata et al 2016</a>].</p><p>Disease-associated variants result in Spred1 proteins incapable of inhibiting Raf1 kinase activation, resulting in attenuated inhibition of downstream Raf-MEK-ERK signaling [<a class="bibr" href="#legius.REF.brems.2007.1120" rid="legius.REF.brems.2007.1120">Brems et al 2007</a>]. This uninhibited signaling and consequent increase in Ras signal propagation is similar to that observed in NF1 and likely results in the clinical overlap of these two conditions.</p><p><b>Mechanism of disease causation.</b> Loss of function</p></div></div><div id="legius.Chapter_Notes"><h2 id="_legius_Chapter_Notes_">Chapter Notes</h2><div id="legius.Acknowledgments"><h3>Acknowledgments</h3><p>John Carey, MD<br />Ludwine Messiaen, PhD<br />Talia Muram, MD</p></div><div id="legius.Author_History"><h3>Author History</h3><p>Eric Legius, MD, PhD (2020-present)<br />Rong Mao, MD; University of Utah (2010-2020)<br />Talia Muram-Zborovski, MD, University of Utah (2010-2015)<br />David Stevenson, MD (2010-present)<br />David Viskochil, MD, PhD; University of Utah (2010-2020)</p></div><div id="legius.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>6 August 2020 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 January 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>12 May 2011 (cd) Revision: Testing Strategy</div></li><li class="half_rhythm"><div>14 October 2010 (me) Review posted live</div></li><li class="half_rhythm"><div>29 April 2010 (ds) Original submission</div></li></ul></div></div><div id="legius.References"><h2 id="_legius_References_">References</h2><div id="legius.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.ablain.2018.1055">Ablain J, Xu M, Rothschild H, Jordan RC, Mito JK, Daniels BH, Bell CF, Joseph NM, Wu H, Bastian BC, Zon LI, Yeh I. Human tumor genomics and zebrafish modeling identify <em>SPRED1</em> loss as a driver of mucosal melanoma. <span><span class="ref-journal">Science. </span>2018;<span class="ref-vol">362</span>:1055–60.</span> [<a href="/pmc/articles/PMC6475924/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6475924</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30385465" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30385465</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.benelli.2015.8">Benelli E, Bruno I, Belcaro C, Ventura A, Berti I. Legius syndrome: case report and review of literature. <span><span class="ref-journal">Ital J Pediatr. </span>2015;<span class="ref-vol">41</span>:8.</span> [<a href="/pmc/articles/PMC4323213/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4323213</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25883013" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25883013</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.brems.2007.1120">Brems H, Chmara M, Sahbatou M, Denayer E, Taniguchi K, Kato R, Somers R, Messiaen L, De Schepper S, Fryns JP, Cools J, Marynen P, Thomas G, Yoshimura A, Legius E. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. <span><span class="ref-journal">Nat Genet. </span>2007;<span class="ref-vol">39</span>:1120–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17704776" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17704776</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.brems.2012.1538">Brems H, Pasmant E, Van Minkelen R, Wimmer K, Upadhyaya M, Legius E, Messiaen L. Review and update of SPRED1 mutations causing Legius syndrome. <span><span class="ref-journal">Hum Mutat. </span>2012;<span class="ref-vol">33</span>:1538–46.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22753041" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22753041</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.castellanos.2020.264">Castellanos E, Rosas I, Negro A, Gel B, Alibés A, Baena N, Pineda M, Pi G, Pintos G, Salvador H, Lázaro C, Blanco I, Vilageliu L, Brems H, Grinberg D, Legius E, Serra E. Mutational spectrum by phenotype: panel-based NGS testing of patients with clinical suspicion of RASopathy and children with multiple café-au-lait macules. <span><span class="ref-journal">Clin Genet. </span>2020;<span class="ref-vol">97</span>:264–75.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31573083" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31573083</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.denayer.2011a.e1985">Denayer E, Chmara M, Brems H, Kievit AM, van Bever Y, Van den Ouweland AM, Van Minkelen R, de Goede-Bolder A, Oostenbrink R, Lakeman P, Beert E, Ishizaki T, Mori T, Keymolen K, Van den Ende J, Mangold E, Peltonen S, Brice G, Rankin J, Van Spaendonck-Zwarts KY, Yoshimura A, Legius E. Legius syndrome in fourteen families. <span><span class="ref-journal">Hum Mutat. </span>2011a;<span class="ref-vol">32</span>:E1985–98.</span> [<a href="/pmc/articles/PMC3038325/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3038325</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21089071" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21089071</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.denayer.2011b.123">Denayer E, Descheemaeker MJ, Stewart DR, Keymolen K, Plasschaert E, Ruppert SL, Snow J, Thurm AE, Joseph LA, Fryns JP, Legius E. Observations on intelligence and behavior in 15 patients with Legius syndrome. <span><span class="ref-journal">Am J Med Genet C Semin Med Genet. </span>2011b;<span class="ref-vol">157C</span>:123–8.</span> [<a href="/pmc/articles/PMC3081633/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3081633</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21495177" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21495177</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.dunzendorfermatt.2016.7497">Dunzendorfer-Matt T, Mercado EL, Maly K, McCormick F, Scheffzek K. The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2016;<span class="ref-vol">113</span>:7497–502.</span> [<a href="/pmc/articles/PMC4941445/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4941445</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27313208" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27313208</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.evans.2016.212">Evans DG, Bowers N, Burkitt-Wright E, Miles E, Garg S, Scott-Kitching V, Penman-Splitt M, Dobbie A, Howard E, Ealing J, Vassalo G, Wallace AJ, Newman W, Huson SM, et al. Comprehensive RNA analysis of the NF1 gene in classically affected NF1 affected individuals meeting NIH criteria has high sensitivity and mutation negative testing is reassuring in isolated cases with pigmentary features only. <span><span class="ref-journal">EBioMedicine. </span>2016;<span class="ref-vol">7</span>:212–20.</span> [<a href="/pmc/articles/PMC4909377/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4909377</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27322474" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27322474</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.giugliano.2019.580">Giugliano T, Santoro C, Torella A, Del Vecchio Blanco F, Grandone A, Onore ME, Melone MAB, Straccia G, Melis D, Piccolo V, Limongelli G, Buono S, Perrotta S, Nigro V, Piluso G. Clinical and genetic findings in children with neurofibromatosis type 1, Legius syndrome, and other related neurocutaneous disorders. <span><span class="ref-journal">Genes (Basel). </span>2019;<span class="ref-vol">10</span>:580.</span> [<a href="/pmc/articles/PMC6722641/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6722641</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31370276" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31370276</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.gutmann.1997.51">Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, Rubenstein A, Viskochil D. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. <span><span class="ref-journal">JAMA. </span>1997;<span class="ref-vol">278</span>:51–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9207339" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9207339</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.hirata.2016.3124">Hirata Y, Brems H, Suzuki M, Kanamori M, Okada M, Morita R, Llano-Rivas I, Ose T, Messiaen L, Legius E, Yoshimura A. Interaction between a domain of the negative regulator of the Ras-ERK pathway, SPRED1 protein, and the GTPase-activating protein-related domain of neurofibromin is implicated in Legius syndrome and neurofibromatosis type 1. <span><span class="ref-journal">J Biol Chem. </span>2016;<span class="ref-vol">291</span>:3124–34.</span> [<a href="/pmc/articles/PMC4751360/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4751360</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26635368" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26635368</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.jobling.2017.1077">Jobling RK, Lara-Corrales I, Hsiao MC, Shugar A, Hedges S, Messiaen L, Kannu P. Mosaicism for a SPRED1 deletion revealed in a patient with clinically suspected mosaic neurofibromatosis. <span><span class="ref-journal">Br J Dermatol. </span>2017;<span class="ref-vol">176</span>:1077–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27423141" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27423141</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.koczkowska.2019.867">Koczkowska M, Callens T, Gomes A, Sharp A, Chen Y, Hicks AD, Aylsworth AS, Azizi AA, Basel DG, Bellus G, Bird LM, Blazo MA, Burke LW, Cannon A, Collins F, DeFilippo C, Denayer E, Digilio MC, Dills SK, Dosa L, Greenwood RS, Griffis C, Gupta P, Hachen RK, Hernández-Chico C, Janssens S, Jones KJ, Jordan JT, Kannu P, Korf BR, Lewis AM, Listernick RH, Lonardo F, Mahoney MJ, Ojeda MM, McDonald MT, McDougall C, Mendelsohn N, Miller DT, Mori M, Oostenbrink R, Perreault S, Pierpont ME, Piscopo C, Pond DA, Randolph LM, Rauen KA, Rednam S, Rutledge SL, Saletti V, Schaefer GB, Schorry EK, Scott DA, Shugar A, Siqveland E, Starr LJ, Syed A, Trapane PL, Ullrich NJ, Wakefield EG, Walsh LE, Wangler MF, Zackai E, Claes KBM, Wimmer K, van Minkelen R, De Luca A, Martin Y, Legius E, Messiaen LM. Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation. <span><span class="ref-journal">Genet Med. </span>2019;<span class="ref-vol">21</span>:867–76.</span> [<a href="/pmc/articles/PMC6752285/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6752285</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30190611" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30190611</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.laycockvan_spyk.2011.93">Laycock-van Spyk S, Jim HP, Thomas L, Spurlock G, Fares L, Palmer-Smith S, Kini U, Saggar A, Patton M, Mautner V, Pilz DT, Upadhyaya M. Identification of five novel SPRED1 germline mutations in Legius syndrome. <span><span class="ref-journal">Clin Genet. </span>2011;<span class="ref-vol">80</span>:93–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21649642" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21649642</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.messiaen.2009.2111">Messiaen L, Yao S, Brems H, Callens T, Sathienkijkanchai A, Denayer E, Spencer E, Arn P, Babovic-Vuksanovic D, Bay C, Bobele G, Cohen BH, Escobar L, Eunpu D, Grebe T, Greenstein R, Hachen R, Irons M, Kronn D, Lemire E, Leppig K, Lim C, McDonald M, Narayanan V, Pearn A, Pederson R, Powell B, Shapiro L, Skidmore D, Tegay D, Thiese H, Zackai E, Vijzelaar R, Taniguchi K, Ayada R, Okamoto F, Yoshimura A, Parret A, Korf B, Legius E. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. <span><span class="ref-journal">JAMA. </span>2009;<span class="ref-vol">302</span>:2111–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19920235" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19920235</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.muramzborovski.2010.1203">Muram-Zborovski TM, Stevenson DA, Viskochil DH, Dries DC, Wilson AR, Mao Rong. SPRED 1 mutations in a neurofibromatosis clinic. <span><span class="ref-journal">J Child Neurol. </span>2010;<span class="ref-vol">25</span>:1203–9.</span> [<a href="/pmc/articles/PMC3243064/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3243064</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20179001" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20179001</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.newell.2019.3163">Newell F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Cui C, Li Z, Kazakoff SH, Burke H, Dodds TJ, Patch AM, Nones K, Tembe V, Shang P, van der Weyden L, Wong K, Holmes O, Lo S, Leonard C, Wood S, Xu Q, Rawson RV, Mukhopadhyay P, Dummer R, Levesque MP, Jönsson G, Wang X, Yeh I, Wu H, Joseph N, Bastian BC, Long GV, Spillane AJ, Shannon KF, Thompson JF, Saw RPM, Adams DJ, Si L, Pearson JV, Hayward NK, Waddell N, Mann GJ, Guo J, Scolyer RA. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. <span><span class="ref-journal">Nat Commun. </span>2019;<span class="ref-vol">10</span>:3163.</span> [<a href="/pmc/articles/PMC6639323/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6639323</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31320640" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31320640</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.nih.1988.172">NIH. National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md, USA, July 13-15, 1987. <span><span class="ref-journal">Neurofibromatosis. </span>1988;<span class="ref-vol">1</span>:172–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/3152465" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3152465</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.nystr_m.2009.693">Nyström AM, Ekvall S, Strömberg B, Holmström G, Theuresson AC, Annerén G, Bondeson ML. A severe form of Noonan syndrome and autosomal dominant café-au-lait spots – evidence for different genetic origins. <span><span class="ref-journal">Acta Paediatr. </span>2009;<span class="ref-vol">98</span>:693–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19120036" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19120036</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.pasmant.2009.1131">Pasmant E, Ballerini P, Lapillonne H, Perot C, Vidaud D, Leverger G, Landman-Parker J. SPRED1 disorder and predisposition to leukemia in children. <span><span class="ref-journal">Blood. </span>2009;<span class="ref-vol">114</span>:1131.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19643996" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19643996</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.pasmant.2015a.631">Pasmant E, Gilbert-Dussardier B, Petit A, de Laval B, Luscan A, Gruber A, Lapillonne H, Deswarte C, Goussard P, Laurendeau I, Uzan B, Pflumio F, Brizard F, Vabres P, Naguibvena I, Fasola S, Millot F, Porteu F, Vidaud D, Landman-Parker J, Ballerini P. SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumor suppressor downregulated in paediatric acute myeloblastic leukaemia. <span><span class="ref-journal">Oncogene. </span>2015a;<span class="ref-vol">34</span>:631–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24469042" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24469042</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.pasmant.2015b.596">Pasmant E, Parfait B, Luscan A, Goussard P, Briand-Suleau A, Laurendeau I, Fouveaut C, Leroy C, Montadert A, Wolkenstein P, Vidaud M, Vidaud D. Neurofibromatosis type 1 molecular diagnosis: what can NGS do for you when you have a large gene with loss of function mutations? <span><span class="ref-journal">Eur J Hum Genet. </span>2015b;<span class="ref-vol">23</span>:596–601.</span> [<a href="/pmc/articles/PMC4402624/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4402624</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25074460" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25074460</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.rahbari.2016.126">Rahbari R, Wuster A, Lindsay SJ, Hardwick RJ, Alexandrov LB, Turki SA, Dominiczak A, Morris A, Porteous D, Smith B, Stratton MR, Hurles ME, et al. Timing, rates and spectra of human germline mutation. <span><span class="ref-journal">Nat Genet. </span>2016;<span class="ref-vol">48</span>:126–33.</span> [<a href="/pmc/articles/PMC4731925/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4731925</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26656846" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26656846</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.rojnueangnit.2015.1052">Rojnueangnit K, Xie J, Gomes A, Sharp A, Callens T, Chen Y, Liu Y, Cochran M, Abbott MA, Atkin J, Babovic-Vuksanovic D, Barnett CP, Crenshaw M, Bartholomew DW, Basel L, Bellus G, Ben-Shachar S, Bialer MG, Bick D, Blumberg B, Cortes F, David KL, Destree A, Duat-Rodriguez A, Earl D, Escobar L, Eswara M, Ezquieta B, Frayling IM, Frydman M, Gardner K, Gripp KW, Hernández-Chico C, Heyrman K, Ibrahim J, Janssens S, Keena BA, Llano-Rivas I, Leppig K, McDonald M, Misra VK, Mulbury J, Narayanan V, Orenstein N, Galvin-Parton P, Pedro H, Pivnick EK, Powell CM, Randolph L, Raskin S, Rosell J, Rubin K, Seashore M, Schaaf CP, Scheuerle A, Schultz M, Schorry E, Schnur R, Siqveland E, Tkachuk A, Tonsgard J, Upadhyaya M, Verma IC, Wallace S, Williams C, Zackai E, Zonana J, Lazaro C, Claes K, Korf B, Martin Y, Legius E, Messiaen L. High incidence of Noonan syndrome features including short stature and pulmonic stenosis in patients carrying NF1 missense mutations affecting p.Arg1809: genotype-phenotype correlation. <span><span class="ref-journal">Hum Mutat. </span>2015;<span class="ref-vol">36</span>:1052–63.</span> [<a href="/pmc/articles/PMC5049609/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5049609</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26178382" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26178382</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.sakai.2015.703">Sakai N, Maeda T, Kawakami H, Uchiyama M, Harada K, Tsuboi R, Mitsuhashi Y. Family with Legius syndrome (neurofibromatosis type 1-like syndrome). <span><span class="ref-journal">J Dermatol. </span>2015;<span class="ref-vol">42</span>:703–5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25981987" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25981987</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.sekelska.2017.205">Sekelska M, Briatkova L, Olcak T, Bolcekova A, Ilencikova D, Kadasi L, Zatkova A. The first Slovak Legius syndrome patient carrying the SPRED1 gene mutation. <span><span class="ref-journal">Gen Physiol Biophys. </span>2017;<span class="ref-vol">36</span>:205–10.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28150585" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28150585</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.spencer.2011.1352">Spencer E, Davis J, Mikhail F, Fu C, Vijzelaar R, Zackai EH, Feret H, Meyn MS, Shugar A, Bellus G, Kocsis K, Kivirikko S, Pöyhönen M, Messiaen L. Identification of SPRED1 deletions using RT-PCR, multiplex ligation-dependent probe amplification and quantitative PCR. <span><span class="ref-journal">Am J Med Genet A. </span>2011;<span class="ref-vol">155A</span>:1352–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21548021" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21548021</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.spurlock.2009.431">Spurlock G, Bennett E, Chuzhanova N, Thomas N, Jim HP, Side L, Davies S, Haan E, Kerr B, Huson SM, Upadhyaya M. SPRED1 mutations (Legius syndrome): another clinically useful genotype for dissecting the NF1 phenotype. <span><span class="ref-journal">J Med Genet. </span>2009;<span class="ref-vol">46</span>:431–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19443465" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19443465</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.stevenson.2009.2150">Stevenson D, Viskochil D. Pigmentary findings in neurofibromatosis type 1-like syndrome (Legius syndrome): potential diagnostic dilemmas. <span><span class="ref-journal">JAMA. </span>2009;<span class="ref-vol">302</span>:2150–1.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19920242" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19920242</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.stowe.2012.1421">Stowe IB, Mercado EL, Stowe TR, Bell EL, Oses-Prieto JA, Hernández H, Burlingame AL, McCormick F. A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibormatosis-1. <span><span class="ref-journal">Genes Dev. </span>2012;<span class="ref-vol">26</span>:1421–6.</span> [<a href="/pmc/articles/PMC3403010/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3403010</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22751498" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22751498</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.tidyman.2009.230">Tidyman WE, Rauen KA. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. <span><span class="ref-journal">Curr Opin Genet Dev. </span>2009;<span class="ref-vol">19</span>:230–6.</span> [<a href="/pmc/articles/PMC2743116/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2743116</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19467855" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19467855</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.wakioka.2001.647">Wakioka T, Sasaki A, Kato R, Shouda T, Matsumoto A, Miyoshi K, Tsuneoka M, Komiya S, Baron R, Yoshimura A. Spred is a Sprouty-related suppressor of Ras signaling. <span><span class="ref-journal">Nature. </span>2001;<span class="ref-vol">412</span>:647–51.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11493923" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11493923</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.witkowski.2020.e1180">Witkowski L, Dillon MW, Murphy E. S Lebo M, Mason-Suares H. Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1. <span><span class="ref-journal">Mol Genet Genomic Med. </span>2020;<span class="ref-vol">8</span>:e1180. </span> [<a href="/pmc/articles/PMC7196473/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7196473</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32107864" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32107864</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="legius.REF.yeh.2019.1068">Yeh I, Jorgenson E, Shen L, Xu M, North JP, Shain AH, Reuss D, Wu H, Robinson WA, Olshen A, von Deimling A, Kwok PY, Bastian BC, Asgari MM. Targeted genomic profiling of acral melanoma. <span><span class="ref-journal">J Natl Cancer Inst. </span>2019;<span class="ref-vol">111</span>:1068–77.</span> [<a href="/pmc/articles/PMC6792090/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6792090</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30657954" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30657954</span></a>]</div></p></li></ul></div></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK47312_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><div class="contrib half_rhythm"><span itemprop="author">Eric Legius</span>, MD, PhD<div class="affiliation small">University of Leuven
|
|
Leuven, Belgium<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="eb.nevuelzu@suigel.cire" class="oemail">eb.nevuelzu@suigel.cire</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">David Stevenson</span>, MD<div class="affiliation small">Stanford University
|
|
Stanford, California<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.drofnats@nevetsad" class="oemail">ude.drofnats@nevetsad</a></div></div></div><h3>Publication History</h3><p class="small">Initial Posting: <span itemprop="datePublished">October 14, 2010</span>; Last Update: <span itemprop="dateModified">August 6, 2020</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2025, University of Washington, Seattle. GeneReviews is
|
|
a registered trademark of the University of Washington, Seattle. All rights
|
|
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
|
|
hereby granted to reproduce, distribute, and translate copies of content materials for
|
|
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2025 University of
|
|
Washington) are included with each copy; (ii) a link to the original material is provided
|
|
whenever the material is published elsewhere on the Web; and (iii) reproducers,
|
|
distributors, and/or translators comply with the <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/GRcopyright_permiss/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">GeneReviews® Copyright Notice and Usage
|
|
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
|
|
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
|
|
use.</p><p class="small">For more information, see the <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/GRcopyright_permiss/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">GeneReviews® Copyright Notice and Usage
|
|
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
|
|
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div></div><h3>Publisher</h3><p><a href="http://www.washington.edu" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">University of Washington, Seattle</a>, Seattle (WA)</p><h3>NLM Citation</h3><p>Legius E, Stevenson D. Legius Syndrome. 2010 Oct 14 [Updated 2020 Aug 6]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. <span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/gene/lhon/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/gene/lenz/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figoblegiusTmoleculargenetictestingused"><div id="legius.T.molecular_genetic_testing_used" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Legius Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK47312/table/legius.T.molecular_genetic_testing_used/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__legius.T.molecular_genetic_testing_used_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_legius.T.molecular_genetic_testing_used_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene <sup>1</sup></th><th id="hd_h_legius.T.molecular_genetic_testing_used_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_legius.T.molecular_genetic_testing_used_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant <sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_legius.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>SPRED1</i>
|
|
</td><td headers="hd_h_legius.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis <sup>3</sup></td><td headers="hd_h_legius.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">89% <sup>4</sup></td></tr><tr><td headers="hd_h_legius.T.molecular_genetic_testing_used_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Deletion/duplication analysis <sup>5</sup></td><td headers="hd_h_legius.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10% <sup>6</sup></td></tr><tr><td headers="hd_h_legius.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown <sup>7</sup></td><td headers="hd_h_legius.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_legius.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~1%</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="legius.TF.1.1"><p class="no_margin">See <a href="/books/NBK47312/?report=reader#legius.molgen.TA">Table A. Genes and Databases</a> for chromosome locus and protein.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2. </dt><dd><div id="legius.TF.1.2"><p class="no_margin">See <a href="#legius.Molecular_Genetics">Molecular Genetics</a> for information on variants detected in this gene.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3. </dt><dd><div id="legius.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <a href="/books/n/gene/app2/?report=reader">here</a>.</p></div></dd></dl><dl class="bkr_refwrap"><dt>4. </dt><dd><div id="legius.TF.1.4"><p class="no_margin">Of individuals evaluated for NF1 without an identifiable <i>NF1</i> pathogenic variant, 3%-25% had an identifiable <i>SPRED1</i> pathogenic variant [<a class="bibr" href="#legius.REF.brems.2007.1120" rid="legius.REF.brems.2007.1120">Brems et al 2007</a>, <a class="bibr" href="#legius.REF.messiaen.2009.2111" rid="legius.REF.messiaen.2009.2111">Messiaen et al 2009</a>, <a class="bibr" href="#legius.REF.pasmant.2009.1131" rid="legius.REF.pasmant.2009.1131">Pasmant et al 2009</a>, <a class="bibr" href="#legius.REF.spurlock.2009.431" rid="legius.REF.spurlock.2009.431">Spurlock et al 2009</a>]. Sequence analysis should identify the majority of individuals without whole-gene deletions, although it is estimated that approximately 1%-2% could have deep intronic variants which could be missed; however, this has not been reported.</p></div></dd></dl><dl class="bkr_refwrap"><dt>5. </dt><dd><div id="legius.TF.1.5"><p class="no_margin">Testing that identifies exon or whole-gene deletions/duplications not detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA. Methods used may include a range of techniques such as quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p></div></dd></dl><dl class="bkr_refwrap"><dt>6. </dt><dd><div id="legius.TF.1.6"><p class="no_margin"><a class="bibr" href="#legius.REF.spencer.2011.1352" rid="legius.REF.spencer.2011.1352">Spencer et al [2011]</a> report that deletions comprise approximately 10% of <i>SPRED1</i> pathogenic variants and include multiexon deletions and whole <i>SPRED1</i> gene deletions</p></div></dd></dl><dl class="bkr_refwrap"><dt>7. </dt><dd><div id="legius.TF.1.7"><p class="no_margin">Sequence analysis in combination with deletion/duplication analysis should identify the majority of individuals, although it is estimated that approximately 1% could have deep intronic variants that could be missed; however, this has not been reported.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figoblegiusTlegiussyndromefrequencyofse"><div id="legius.T.legius_syndrome_frequency_of_se" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Legius Syndrome: Frequency of Select Features</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK47312/table/legius.T.legius_syndrome_frequency_of_se/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__legius.T.legius_syndrome_frequency_of_se_lrgtbl__"><table><thead><tr><th id="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Feature</th><th id="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">% of Persons with Feature</th><th id="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Café au lait macules</b>
|
|
</td><td headers="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">>99%</td><td headers="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Skin freckling</b>
|
|
</td><td headers="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">30%-50%</td><td headers="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age dependent</td></tr><tr><td headers="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Macrocephaly</b>
|
|
</td><td headers="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20%</td><td headers="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Short stature</b>
|
|
</td><td headers="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">12%</td><td headers="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Neurobehavioral/developmental issues</b>
|
|
</td><td headers="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">30%</td><td headers="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Multiple lipomas</b>
|
|
</td><td headers="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">18%</td><td headers="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In adults</td></tr><tr><td headers="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Pectus deformity</b>
|
|
</td><td headers="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">12%</td><td headers="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/noonan/?report=reader">
|
|
<b>Noonan</b>
|
|
</a>
|
|
<b>-like facial features</b>
|
|
</td><td headers="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15%</td><td headers="hd_h_legius.T.legius_syndrome_frequency_of_se_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figoblegiusTdisorderswithmultiplecafau"><div id="legius.T.disorders_with_multiple_caf_au" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Disorders with Multiple Café au Lait Macules of Interest in the Differential Diagnosis of Legius Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK47312/table/legius.T.disorders_with_multiple_caf_au/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__legius.T.disorders_with_multiple_caf_au_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Additional Clinical Features Not Associated w/Legius Syndrome</th></tr></thead><tbody><tr><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>BLM</i>
|
|
</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/bloom/?report=reader">Bloom syndrome</a>
|
|
</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pre- & postnatal severe growth retardation, susceptibility to infections, high incidence of hematological malignancies</td></tr><tr><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>BRAF</i><br /><i>HRAS</i><br /><i>KRAS</i><br /><i>LZTR1</i><br /><i>MAP2K1</i><br /><i>NRAS</i><br /><i>PTPN11</i><br /><i>RAF1</i><br /><i>RAF1</i><br /><i>RIT1</i><br /><i>SOS1</i> <sup>1</sup></td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/costello/?report=reader">Costello syndrome</a>
|
|
</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Coarse facial features, ulnar deviation of wrist & fingers, ↑ incidence of cardiomyopathy, arrhythmia, rhabdomyosarcoma, neuroblastoma, bladder transitional cell carcinoma</td></tr><tr><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/noonan/?report=reader">Noonan syndrome</a> <sup>2</sup></td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD<br />(AR) <sup>3</sup></td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypertrophic cardiomyopathy</td></tr><tr><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/leopard/?report=reader">Noonan syndrome w/multiple lentigines</a>
|
|
</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Lentigines, hypertrophic cardiomyopathy</td></tr><tr><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/cfc/?report=reader">Cardiofaciocutaneous syndrome</a>
|
|
</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Moderate to severe intellectual disability, skin abnormalities (hyperkeratosis), sparse hair</td></tr><tr><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>BRCA2</i><br /><i>BRIP1</i><br /><i>FANCA</i><br /><i>FANCB</i><br /><i>FANCC</i><br /><i>FANCD2</i><br /><i>FANCE</i><br /><i>FANCF</i><br /><i>FANCG</i><br /><i>FANCI</i><br />(21 genes) <sup>4</sup></td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/fa/?report=reader">Fanconi anemia</a>
|
|
</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR<br />AD<br />XL</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bone marrow failure, skeletal limb malformations, microcephaly, malignancies</td></tr><tr><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>GNAS</i>
|
|
</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/mccune-albright/?report=reader">Fibrous dysplasia/McCune-Albright syndrome</a>
|
|
</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 5.</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Fibrous bone dysplasia, precocious puberty, hyperpigmentation w/irregular borders</td></tr><tr><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>MLH1</i>
|
|
<br />
|
|
<i>MSH2</i>
|
|
<br />
|
|
<i>MSH6</i>
|
|
<br />
|
|
<i>PMS2</i>
|
|
</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CMMRD (See <a href="/books/n/gene/hnpcc/?report=reader">Lynch Syndrome</a>.)</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">High frequency of childhood malignancies, pilomatricomas</td></tr><tr><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>NF1</i>
|
|
</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/nf1/?report=reader">Neurofibromatosis 1</a>
|
|
</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Optic pathway & other brain glioma, Lisch nodules, choroidal abnormalities, neurofibromas, congenital bowing of limbs, pseudarthrosis, sphenoid bone dysplasia</td></tr><tr><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>PTEN</i>
|
|
</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bannayan-Riley-Ruvalcaba syndrome (See <a href="/books/n/gene/phts/?report=reader"><i>PTEN</i> Hamartoma Tumor Syndrome</a>.)</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Extreme macrocephaly, ↑ risk for cancer & benign skin tumors, hamartomatous polyps</td></tr><tr><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>TSC1</i>
|
|
<br />
|
|
<i>TSC2</i>
|
|
</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/tuberous-sclerosis/?report=reader">Tuberous sclerosis complex</a>
|
|
</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_legius.T.disorders_with_multiple_caf_au_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Angiofibromas, shagreen patches, ungual fibromas, brain abnormalities (nodules, dysplasia, astrocytomas), renal angiomyolipomas, cardiac rhabdomyomas</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">AD = autosomal dominant; AR = autosomal recessive; CMMRD = constitutional mismatch repair deficiency; MOI = mode of inheritance; XL = X-linked</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="legius.TF.3.1"><p class="no_margin">Genes associated with RASopathies are grouped together in this table to avoid redundancy. See the linked <i>GeneReviews</i> for specific gene-phenotype relationships.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2. </dt><dd><div id="legius.TF.3.2"><p class="no_margin">At least one individual with Legius syndrome was previously diagnosed as having Noonan syndrome [<a class="bibr" href="#legius.REF.brems.2007.1120" rid="legius.REF.brems.2007.1120">Brems et al 2007</a>].</p></div></dd></dl><dl class="bkr_refwrap"><dt>3. </dt><dd><div id="legius.TF.3.3"><p class="no_margin">Noonan syndrome is most often inherited in an autosomal dominant manner. Noonan syndrome caused by pathogenic variants in <i>LZTR1</i> can be inherited in either an autosomal dominant or an autosomal recessive manner.</p></div></dd></dl><dl class="bkr_refwrap"><dt>4. </dt><dd><div id="legius.TF.3.4"><p class="no_margin">Listed genes represent the most common genetic causes; see <a href="/books/n/gene/fa/?report=reader">Fanconi Anemia</a> for additional associated genes.</p></div></dd></dl><dl class="bkr_refwrap"><dt>5. </dt><dd><div id="legius.TF.3.5"><p class="no_margin"><a href="/books/n/gene/mccune-albright/?report=reader">Fibrous dysplasia/McCune-Albright syndrome</a>, a sporadically occurring disorder, is caused by an early embryonic postzygotic somatic activating (gain-of-function) pathogenic variant in <i>GNAS</i> (encoding the cAMP pathway-associated G-protein, Gsα).</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figoblegiusTrecommendedevaluationsfollowi"><div id="legius.T.recommended_evaluations_followi" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Recommended Evaluations Following Initial Diagnosis in Individuals with Legius Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK47312/table/legius.T.recommended_evaluations_followi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__legius.T.recommended_evaluations_followi_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_legius.T.recommended_evaluations_followi_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_legius.T.recommended_evaluations_followi_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_legius.T.recommended_evaluations_followi_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_legius.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Development</b>
|
|
</td><td headers="hd_h_legius.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Developmental assessment</td><td headers="hd_h_legius.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Incl motor, adaptive, cognitive, & speech/language eval</div></li><li class="half_rhythm"><div>Eval for early intervention / special education</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_legius.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Psychiatric/</b>
|
|
<br />
|
|
<b>Behavioral</b>
|
|
</td><td headers="hd_h_legius.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neuropsychiatric eval</td><td headers="hd_h_legius.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Persons age >12 mos: screening for behavior concerns incl ADHD</td></tr><tr><td headers="hd_h_legius.T.recommended_evaluations_followi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Genetic</b>
|
|
<br />
|
|
<b>counseling</b>
|
|
</td><td headers="hd_h_legius.T.recommended_evaluations_followi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">By genetics professionals <sup>1</sup></td><td headers="hd_h_legius.T.recommended_evaluations_followi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To inform affected persons & their families re nature, MOI, & implications of Legius syndrome to facilitate medical & personal decision making</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">ADHD = attention-deficit/hyperactivity disorder; MOI = mode of inheritance</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="legius.TF.4.1"><p class="no_margin">Geneticist, certified genetic counselor, or certified advanced genetic nurse</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figoblegiusTtreatmentofmanifestationsin"><div id="legius.T.treatment_of_manifestations_in" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Treatment of Manifestations in Individuals with Legius Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK47312/table/legius.T.treatment_of_manifestations_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__legius.T.treatment_of_manifestations_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_legius.T.treatment_of_manifestations_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Manifestation/Concern</th><th id="hd_h_legius.T.treatment_of_manifestations_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th></tr></thead><tbody><tr><td headers="hd_h_legius.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Developmental delay /</b>
|
|
<br />
|
|
<b>Intellectual disability</b>
|
|
</td><td headers="hd_h_legius.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Adjuvant therapies incl PT, OT, & speech therapy for persons w/identified developmental delays</div></li><li class="half_rhythm"><div>Individualized education plans for learning disorders & school performance issues</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_legius.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Psychiatric/Behavioral</b>
|
|
</td><td headers="hd_h_legius.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consideration of behavioral modification or pharmacologic adjuvant therapy for individuals w/ADHD</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">ADHD = attention-deficit/hyperactivity disorder; OT = occupational therapy; PT = physical therapy</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figoblegiusTrecommendedsurveillanceforin"><div id="legius.T.recommended_surveillance_for_in" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p>Recommended Surveillance for Individuals with Legius Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK47312/table/legius.T.recommended_surveillance_for_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__legius.T.recommended_surveillance_for_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_legius.T.recommended_surveillance_for_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_legius.T.recommended_surveillance_for_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_legius.T.recommended_surveillance_for_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequency</th></tr></thead><tbody><tr><td headers="hd_h_legius.T.recommended_surveillance_for_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Development</b>
|
|
</td><td headers="hd_h_legius.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Monitor developmental progress & educational needs.</td><td headers="hd_h_legius.T.recommended_surveillance_for_in_1_1_1_3" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;">At each visit</td></tr><tr><td headers="hd_h_legius.T.recommended_surveillance_for_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Psychiatric/Behavioral</b>
|
|
</td><td headers="hd_h_legius.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Behavioral assessment for ADHD</td></tr><tr><td headers="hd_h_legius.T.recommended_surveillance_for_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Vascular anomalies <sup>1</sup></b>
|
|
</td><td headers="hd_h_legius.T.recommended_surveillance_for_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Blood pressure assessment</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">ADHD = attention-deficit/hyperactivity disorder</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="legius.TF.6.1"><p class="no_margin">Although vascular abnormalities have been reported in a few individuals with Legius syndrome, hypertension has not been reported. However, given the prevalence of vascular abnormalities and hypertension in NF1, it would seem appropriate to have regular blood pressure monitoring at each physician visit.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figoblegiusmolgenTA"><div id="legius.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Legius Syndrome: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK47312/table/legius.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__legius.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_legius.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_legius.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_legius.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_legius.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_legius.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_legius.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_legius.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/161742" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>SPRED1</i>
|
|
</a>
|
|
</td><td headers="hd_b_legius.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=161742" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">15q14</a>
|
|
</td><td headers="hd_b_legius.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/Q7Z699" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Sprouty-related, EVH1 domain-containing protein 1</a>
|
|
</td><td headers="hd_b_legius.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.arup.utah.edu/database/SPRED1/SPRED1_welcome.php" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Legius Syndrome and SPRED1</a>
|
|
<br />
|
|
<a href="http://www.lovd.nl/SPRED1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">SPRED1 @ LOVD</a>
|
|
<br />
|
|
<a href="http://databases.lovd.nl/shared/genes/SPRED1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">SPRED1 database</a>
|
|
</td><td headers="hd_b_legius.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SPRED1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">SPRED1</a>
|
|
</td><td headers="hd_b_legius.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SPRED1[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">SPRED1</a>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div id="legius.TFA.1"><p class="no_margin">Data are compiled from the following standard references: gene from
|
|
<a href="http://www.genenames.org/index.html" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">HGNC</a>;
|
|
chromosome locus from
|
|
<a href="http://www.omim.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">OMIM</a>;
|
|
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">UniProt</a>.
|
|
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
|
|
<a href="/books/n/gene/app1/?report=reader">here</a>.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figoblegiusmolgenTB"><div id="legius.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Legius Syndrome (<a href="/omim/609291,611431" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK47312/table/legius.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__legius.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/609291" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">609291</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SPROUTY-RELATED EVH1 DOMAIN-CONTAINING PROTEIN 1; SPRED1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/611431" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">611431</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LEGIUS SYNDROME; LGSS</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script><script type="text/javascript">if (typeof (jQuery) != 'undefined') { (function ($) { $(function () { var min = Math.ceil(1); var max = Math.floor(100000); var randomNum = Math.floor(Math.random() * (max - min)) + min; var surveyUrl = "/projects/Gene/portal/surveys/seqdbui-survey.js?rando=" + randomNum.toString(); $.getScript(surveyUrl, function () { try { ncbi.seqDbUISurvey.init(); } catch (err) { console.info(err); } }).fail(function (jqxhr, settings, exception) { console.info('Cannot load survey script', jqxhr); });; }); })(jQuery); };</script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|